CLAZAKIZUMAB (ANTI-IL-6 MONOCLONAL) TREATMENT OF PATIENTS WITH CHRONIC & ACTIVE ANTIBODY-MEDIATED REJECTION POST-KIDNEY TRANSPLANTATION (NCT03380377)

被引：0
|
作者：
Jordan, Stanley [1 ]
Ammerman, Noriko [1 ]
Toyoda, Mieko [2 ]
Ge, Shili [2 ]
Huang, Edmund [1 ]
Peng, Alice [1 ]
Sethi, Supreet [1 ]
Najjar, Reiad [1 ]
Ortiz, Edwin [2 ]
Chu, Maggie [2 ]
De Guzman, Abner [2 ]
Kim, Irene [1 ]
Lim, Kathlyn [1 ]
Choi, Jua [1 ]
Vo, Ashley A. [1 ]
机构：
[1] Cedars Sinai Med Ctr, Kidney Transplant, Los Angeles, CA 90048 USA
[2] Cedars Sinai Med Ctr, Transplant Immunol Lab, Los Angeles, CA 90048 USA
来源：
TRANSPLANTATION | 2020年 / 104卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
380.2
引用
收藏
页码：S67 / S68
页数：2
相关论文
共 50 条
  • [1] Clazakizumab (Anti-IL-6 Monoclonal) as an Agent to Reduce Donor Specific Hla Antibodies (DSA) and Improve Outcomes in Patients with Chronic & Active Antibody-Mediated Rejection Post-Kidney Transplantation (NCT03380377)
    Jordan, S. C.
    Ammerman, N.
    Toyoda, M.
    Ge, S.
    Huang, E.
    Peng, A.
    Sethi, S.
    Najjar, R.
    Ortiz, E.
    Chu, M.
    De Guzman, A.
    Kim, I.
    Lim, K.
    Choi, J.
    Vo, A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 : 848 - 849
  • [2] Clazakizumab (Anti-IL6 Monoclonal) to Reduce Donor Specific HLA Antibodies (DSA) and Improve Outcomes in Post- Kidney Transplant Patients with Chronic Active Antibody Mediated Rejection (NCT03380377)
    Jordan, S. C.
    Ammerman, N.
    Huang, E.
    Peng, A.
    Najjar, R.
    Kim, I.
    Hernando, K.
    Bui, V.
    Choi, J.
    Lim, K.
    Badash, N.
    Gillespie, M.
    Vo, A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2023, 23 (06) : S489 - S489
  • [3] EVALUATION OF CLAZAKIZUMAB (ANTI-IL-6) FOR TREATMENT OF KIDNEY TRANSPLANT RECIPIENTS WITH CHRONIC & ACTIVE ANTIBODY MEDIATED REJECTION
    Jordan, Stanley
    Ammerman, Noriko
    Toyoda, Mieko
    Huang, Edmund
    Nast, Cynthia
    Peng, Alice
    Sethi, Supreet
    Najjar, Reiad
    Kim, Irene
    Lim, Kathlyn
    Choi, Jua
    Vo, Ashley
    TRANSPLANT INTERNATIONAL, 2019, 32 : 400 - 401
  • [4] A Randomized Clinical Trial of Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Kidney Transplant Rejection
    Doberer, Konstantin
    Duerr, Michael
    Halloran, Philip F.
    Eskandary, Farsad
    Budde, Klemens
    Regele, Heinz
    Reeve, Jeff
    Borski, Anita
    Kozakowski, Nicolas
    Reindl-Schwaighofer, Roman
    Waiser, Johannes
    Lachmann, Nils
    Schranz, Sabine
    Firbas, Christa
    Muehlbacher, Jakob
    Gelbenegger, Georg
    Perkmann, Thomas
    Wahrmann, Markus
    Kainz, Alexander
    Ristl, Robin
    Halleck, Fabian
    Bond, Gregor
    Chong, Edward
    Jilma, Bernd
    Boehmig, Georg A.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (03): : 708 - 722
  • [5] Clazakizumab as an Agent to Reduce Donor Specific HLA Antibodies and Improve Outcomes in Patients with Chronic & Active Antibody-Mediated Rejection Post-Kidney Transplantation.
    Jordan, S. C.
    Ammerman, N.
    Toyoda, M.
    Huang, E.
    Nast, C. C.
    Peng, A.
    Sethi, S.
    Najjar, R.
    Kim, I.
    Lim, K.
    Choi, J.
    Vo, A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 : 452 - 452
  • [6] Evaluation of Clazakizumab (Anti-Interleukin-6) in Patients With Treatment-Resistant Chronic Active Antibody-Mediated Rejection of Kidney Allografts
    Jordan, Stanley C.
    Ammerman, Noriko
    Choi, Jua
    Huang, Edmund
    Najjar, Reiad
    Peng, Alice
    Sethi, Supreet
    Sandhu, Rana
    Atienza, Janet
    Toyoda, Mieko
    Ge, Shili
    Lim, Kathlyn
    Gillespie, Matthew
    Zhang, Xiaohai
    Haas, Mark
    Vo, Ashley
    KIDNEY INTERNATIONAL REPORTS, 2022, 7 (04): : 720 - 731
  • [7] Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Rejection - Molecular Rebound Phenomena Under IL-6 Blockade?
    Borski, A.
    Haindl, S.
    Duerr, M.
    Budde, K.
    Schranz, S.
    Eskandary, F. A.
    Doberer, K.
    Halloran, P. F.
    Chong, E.
    Jilma, B.
    Boehmig, G. A.
    Wahrmann, M.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 : 853 - 853
  • [8] ANTI-IL-6 ANTIBODY CLAZAKIZUMAB IN LATE ANTIBODY-MEDIATED REJECTION - MOLECULAR REBOUND PHENOMENA UNDER IL-6 BLOCKADE?
    Borski, Anita
    Haindl, Susanne
    Durr, Michael
    Budde, Klemens
    Schranz, Sabine
    Eskandary, Farsad A.
    Doberer, Konstantin
    Halloran, Philip F.
    Chong, Edward
    Jilma, Bernd
    Bohmig, Georg A.
    Wahrmann, Markus
    TRANSPLANTATION, 2020, 104 (09) : S67 - S67
  • [9] Clazakizumab (CLZ, Anti-IL-6 Monoclonal Antibody) Treatment of Patients (Pts) with Chronic Antibody-Mediated Rejection (cABMR) Reduces Total Immunoglobulin (Ig) and Anti-HLA IgG Antibody Levels.
    Shin, B.
    Ammerman, N. F.
    Vo, A. A.
    Zhang, X.
    Jordan, S. C.
    Toyoda, M.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 : 667 - 667
  • [10] Monitoring Inflammatory Cytokine Levels in Kidney Transplant Patients (KTx Pts) with Chronic Antibody Mediated Rejection (cABMR) Treated with Clazakizumab (CLZ, Humanized Anti-IL-6 Monoclonal Antibody).
    Ge, S.
    Petrosyan, A.
    Chu, M.
    Ammerman, N.
    Vo, A.
    Jordan, S. C.
    Zhang, X.
    Toyoda, M.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 : 661 - 661
12345